Liangliang Hao, PhD
Assistant Professor
Boston University College of Engineering
Biomedical Engineering

PhD, Northwestern University
MS, University of Waterloo
BS, Nankai University

Precision medicine has transformative impact in managing heterogeneous disorders including cancer, metabolic, and neurological diseases. At the living interface of precision engineering and health, the Hao laboratory will develop molecular and cellular tools to precisely track and control disease biology in intact organisms. Our specific research interests include (1) noninvasive disease detection and treatment monitoring at the Point-of-Care, (2) tissue-specific transcriptome engineering, and (3) multimodal systemic imaging. These projects will shed light on the dynamic interplay of diseased cells and their microenvironment. We seek to use these insights to address grand challenges of getting precision medicine into healthcare practice such as comorbidities, timely interventions, and access in low-resource areas.

Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis
03/01/2023 - 02/28/2026 (PI)
NIH/National Cancer Institute

CRISPR-Cas-amplified biomarkers for disease detection and monitoring at the point of care
11/01/2023 - 10/31/2024 (PI)
PhRMA Foundation


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Hao L, Zhao RT, Welch NL, Tan EKW, Zhong Q, Harzallah NS, Ngambenjawong C, Ko H, Fleming HE, Sabeti PC, Bhatia SN. CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics. Nat Nanotechnol. 2023 Jul; 18(7):798-807. PMID: 37095220; PMCID: PMC10359190; DOI: 10.1038/s41565-023-01372-9;
  2. Hao L, Rohani N, Zhao RT, Pulver EM, Mak H, Kelada OJ, Ko H, Fleming HE, Gertler FB, Bhatia SN. Microenvironment-triggered multimodal precision diagnostics. Nat Mater. 2021 Oct; 20(10):1440-1448. PMID: 34267368; DOI: 10.1038/s41563-021-01042-y;
  3. Hao L, Zhao RT, Ngambenjawong C, Fleming HE, Bhatia S. CRISPR-Cas-amplified urine biomarkers for multiplexed and portable cancer diagnostics. bioRxiv. 2020. View Publication
  4. Tian C, Öhlund D, Rickelt S, Lidström T, Huang Y, Hao L, Zhao RT, Franklin O, Bhatia SN, Tuveson DA, Hynes RO. Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2020 Apr 01; 80(7):1461-1474. PMID: 32029550; PMCID: PMC7127978; DOI: 10.1158/0008-5472.CAN-19-2578;
  5. Boehnke N, Correa S, Hao L, Wang W, Straehla JP, Bhatia SN, Hammond PT. Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing. Angew Chem Int Ed Engl. 2020 Feb 10; 59(7):2776-2783. PMID: 31747099; PMCID: PMC7002217; DOI: 10.1002/anie.201911762;
  6. Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ. Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget. 2019 Sep 03; 10(51):5349-5358. PMID: 31523393; PMCID: PMC6731108; DOI: 10.18632/oncotarget.27160;
  7. Rohani N, Hao L, Alexis MS, Joughin BA, Krismer K, Moufarrej MN, Soltis AR, Lauffenburger DA, Yaffe MB, Burge CB, Bhatia SN, Gertler FB. Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes. Cancer Res. 2019 Apr 15; 79(8):1952-1966. PMID: 30755444; PMCID: PMC6467770; DOI: 10.1158/0008-5472.CAN-18-1604;
  8. Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 Nov; 17(11):2377-2388. PMID: 30097486; PMCID: PMC6298224; DOI: 10.1158/1535-7163.MCT-17-1090;
  9. Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ. Personalized RNA Medicine for Pancreatic Cancer. Clin Cancer Res. 2018 Apr 01; 24(7):1734-1747. PMID: 29330203; DOI: 10.1158/1078-0432.CCR-17-2733;
  10. Hao L, Lo J, Bhatia S. Tumor penetrating RNA delivery for therapeutic benefit of pancreatic cancer. Cancer Research. 2017; 77(13_Suppl):5088.
Showing 10 of 32 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 32 publications over 14 distinct years, with a maximum of 6 publications in 2012


NIH-NCI: Pathway to Independence Award (K99/R00)
American Cancer Society: Postdoctoral Fellowship Award
Ludwig Molecular Oncology: Postdoctoral Fellowship
International Student Research Fellowship: Howard Hughes Medical Institute
International Institute for Nanotechnology: Outstanding Research Award
Oligonucleotide Therapeutics Society: Nucleic Acid Research Award
Inaugural HHMI Leading Edge Symposium: Leading Edge Fellow
Bayer Science & Education Foundation: Bayer Lindau Fellow
MIT Marble Center for Cancer Nanomedicine: Convergence Scholar
Contact for Mentoring:

44 Cummington St
Boston MA 02215
Google Map

Hao's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department